Aligos Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALGS research report →
Range $20 – $20
Price Chart
About the company
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB).
- CEO
- Lawrence Blatt
- IPO
- 2020
- Employees
- 82
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on ALGS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $33.79M
- P/E
- -0.75
- Fwd P/E
- 9.55
- PEG
- 0.00
- P/S
- 1.07
- P/B
- 1.79
- EV/EBITDA
- -0.10
- Div Yield
- 0.00%
- Gross Margin
- 99.18%
- Op Margin
- -250.63%
- Net Margin
- -241.01%
- ROE
- -160.72%
- ROIC
- -191.73%
Latest fiscal year · YoY change
- Revenue
- $2.19M-44.6%
- Gross Profit
- $1.26M-68.2%
- Op Income
- $-87,985,000
- Net Income
- $-24,193,000+81.6%
- EPS
- $-2.45+88.3%
- OCF Growth
- -2.2%
- FCF Growth
- -2.6%
- 52W High
- $13.69
- 52W Low
- $3.98
- 50D MA
- $5.80
- 200D MA
- $6.67
- Beta
- 2.33
- RSI (14)
- 45
- Avg Volume
- 110.08K
No earnings-call transcripts are available for ALGS yet.
- Free Float
- 77.5%
- Shares Outstanding
- 6.19M
- Float Shares
- 4.80M
of shares held by institutions
34 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Deep Track Capital, LP | 444.11K | 0 |
| Alyeska Investment Group, L.P. | 412.00K | 0 |
| Sio Capital Management, LLC | 327.24K | 0 |
| Marshall Wace, Llp | 246.58K | ▼ 20.56K |
| Vanguard Group Inc | 200.40K | ▲ 28.71K |
| Woodline Partners LP | 177.36K | 0 |
| Vanguard Capital Management LLC | 175.54K | ▼ 2.72K |
| Baker Bros. Advisors LP | 83.06K | 0 |
| Hhlr Advisors, Ltd. | 76.25K | 0 |
| D. E. Shaw & Co., Inc. | 66.46K | ▲ 55.48K |
| Ubs Group AG | 59.99K | ▲ 22.93K |
| Geode Capital Management, LLC | 47.17K | ▼ 2.80K |
Held by 28 ETFs
Biggest fund positions in ALGS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Preston Heather | other | 5,860 |
| Jun 25, 26 | Chavez Margarita | other | 5,860 |
| Jun 25, 26 | Martell Bridget A | other | 5,860 |
| Jun 25, 26 | Scopa James Paul | other | 5,860 |
| Jun 25, 26 | Nuechterlein Carole | other | 5,860 |
| Jun 25, 26 | Hirth Peter | other | 5,860 |
| Mar 9, 26 | Symons Julian A. | other | 23,310 |
| Mar 9, 26 | Aneja Nikhil | other | 9,450 |
| Mar 9, 26 | Calhoun Lesley Ann | other | 37,485 |
| Mar 9, 26 | BLATT LAWRENCE | other | 105,840 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALGS coverage
Recent articles, reports, and earnings notes.
No research on ALGS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALGS report →Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
globenewswire.com · Oct 5
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
gurufocus.com · Sep 27
Aligos Therapeutics (NASDAQ:ALGS) & Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head Analysis
defenseworld.net · Sep 21
Aligos Therapeutics, Inc. $ALGS Shares Bought by Bank of America Corp DE
defenseworld.net · Sep 4
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
globenewswire.com · Sep 2
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
globenewswire.com · Aug 12
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
globenewswire.com · Jul 30
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
globenewswire.com · Jul 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.